Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA), commonly called a superbug, is a highly alarming antibiotic-resistant population of Staphylococcus aureus (S. aureus) bacteria. Vancomycin (VAN) was first approved by the FDA in 1988, and it is still regarded a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kushal Vanamala, Ketki Bhise, Hiram Sanchez, Razieh Kebriaei, Duy Luong, Samaresh Sau, Hosam Abdelhady, Michael J. Rybak, David Andes, Arun K. Iyer
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	vancomycin liposomes MRSA thigh infection antibacterial resistance Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/1391a5fd18734e85bf0de9c19fde62e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1391a5fd18734e85bf0de9c19fde62e1
record_format	dspace
spelling	oai:doaj.org-article:1391a5fd18734e85bf0de9c19fde62e12021-11-25T18:40:44ZFolate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i>10.3390/pharmaceutics131117911999-4923https://doaj.org/article/1391a5fd18734e85bf0de9c19fde62e12021-10-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1791https://doaj.org/toc/1999-4923Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), commonly called a superbug, is a highly alarming antibiotic-resistant population of <i>Staphylococcus aureus (S. aureus)</i> bacteria. Vancomycin (VAN) was first approved by the FDA in 1988, and it is still regarded as the treatment of choice for MRSA. The efficacy of VAN treatment has become less effective due to the development of VAN resistance in MRSA and the potential for nephrotoxicity. This study aims to improve the efficacy of VAN treatment by identifying the folate receptor for MRSA infected tissues and developing folate decorated lipid nanoparticles containing VAN (LVAN). In comparison to conventional VAN, LVAN showed a higher bactericidal effect and a superior ability to inhibit biofilm in MRSA with an enhanced accumulation in MRSA infected thigh tissues and a reduced accumulation in kidney. The results suggested that LVAN is a promising candidate to overcome the current limitations of bacterial resistance and adverse side effects in kidneys found in VAN.Kushal VanamalaKetki BhiseHiram SanchezRazieh KebriaeiDuy LuongSamaresh SauHosam AbdelhadyMichael J. RybakDavid AndesArun K. IyerMDPI AGarticlevancomycinliposomesMRSAthigh infectionantibacterial resistancePharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1791, p 1791 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	vancomycin liposomes MRSA thigh infection antibacterial resistance Pharmacy and materia medica RS1-441
spellingShingle	vancomycin liposomes MRSA thigh infection antibacterial resistance Pharmacy and materia medica RS1-441 Kushal Vanamala Ketki Bhise Hiram Sanchez Razieh Kebriaei Duy Luong Samaresh Sau Hosam Abdelhady Michael J. Rybak David Andes Arun K. Iyer Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i>
description	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), commonly called a superbug, is a highly alarming antibiotic-resistant population of <i>Staphylococcus aureus (S. aureus)</i> bacteria. Vancomycin (VAN) was first approved by the FDA in 1988, and it is still regarded as the treatment of choice for MRSA. The efficacy of VAN treatment has become less effective due to the development of VAN resistance in MRSA and the potential for nephrotoxicity. This study aims to improve the efficacy of VAN treatment by identifying the folate receptor for MRSA infected tissues and developing folate decorated lipid nanoparticles containing VAN (LVAN). In comparison to conventional VAN, LVAN showed a higher bactericidal effect and a superior ability to inhibit biofilm in MRSA with an enhanced accumulation in MRSA infected thigh tissues and a reduced accumulation in kidney. The results suggested that LVAN is a promising candidate to overcome the current limitations of bacterial resistance and adverse side effects in kidneys found in VAN.
format	article
author	Kushal Vanamala Ketki Bhise Hiram Sanchez Razieh Kebriaei Duy Luong Samaresh Sau Hosam Abdelhady Michael J. Rybak David Andes Arun K. Iyer
author_facet	Kushal Vanamala Ketki Bhise Hiram Sanchez Razieh Kebriaei Duy Luong Samaresh Sau Hosam Abdelhady Michael J. Rybak David Andes Arun K. Iyer
author_sort	Kushal Vanamala
title	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i>
title_short	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i>
title_full	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i>
title_fullStr	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i>
title_full_unstemmed	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i>
title_sort	folate functionalized lipid nanoparticles for targeted therapy of methicillin-resistant <i>staphylococcus aureus</i>
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1391a5fd18734e85bf0de9c19fde62e1
work_keys_str_mv	AT kushalvanamala folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT ketkibhise folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT hiramsanchez folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT raziehkebriaei folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT duyluong folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT samareshsau folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT hosamabdelhady folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT michaeljrybak folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT davidandes folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi AT arunkiyer folatefunctionalizedlipidnanoparticlesfortargetedtherapyofmethicillinresistantistaphylococcusaureusi
_version_	1718410816527532032

Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i>

Ejemplares similares